Department of Internal Medicine, Rheumatology and Clinical Immunology, Medical University of Silesia, Katowice, Poland.
Pol Arch Intern Med. 2020 Aug 27;130(7-8):655-661. doi: 10.20452/pamw.15366. Epub 2020 May 19.
Coronavirus disease 2019 (COVID‑19) is an infectious disease that became a global health emergency. This review focuses on the aspects of COVID‑19 pertaining to rheumatology, including signs and symptoms akin to those observed in rheumatic disorders, risk of infection or severe course of the disease in patients with a pre‑ existing rheumatic disease and those receiving antirheumatic or immunosuppressive medication, as well as potential use of antirheumatic or anticytokine therapeutic strategies that are already applied in rheumatology (among others, chloroquine, hydroxychloroquine, tocilizumab, and baricitinib) in patients with COVID‑19.
新型冠状病毒病 2019（COVID-19）是一种传染病，已成为全球卫生紧急事件。本综述重点介绍与风湿病学相关的 COVID-19 方面，包括类似于风湿性疾病中观察到的体征和症状、患有风湿性疾病或正在接受抗风湿或免疫抑制药物治疗的患者感染或疾病严重程度的风险，以及在 COVID-19 患者中应用已在风湿病学中应用的抗风湿或抗细胞因子治疗策略的潜在用途（包括氯喹、羟氯喹、托珠单抗和巴瑞替尼）。
